Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Clinical trial findings from the 2017 Liver Meeting
We are beginning to see the fruits of our efforts in eradicating this disease.
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
Such a benefit is associated with considerable cost savings.
Having hepatitis C with evidence of resistance to medications did not impact the chances of a cure in a recent study.
In a recent study, half of those cured of hepatitis C developed signs of non-alcoholic fatty liver disease (NAFLD).
A pooled analysis of numerous studies found the safety and efficacy of the regimen was comparable between those under and those over 65.
The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.
The prompts did not, however, get sufficient numbers of those born between 1945 and 1965 tested for the virus.
The surgical practice is common in the United Kingdom but rare in the United States.
These include herbal supplements and those marketed for weight lifters or dieters, which may contain harmful unlisted ingredients.
Researchers also found that disease severity is worse for those with alcoholic cirrhosis compared with those with nonalcoholic cirrhosis.
By modifying these barriers, clinicians hope to treat more hep C among patients undergoing opioid addiction treatment.
Sexual transmission is likely driving this increase; meth and injection drug use are also risk factors.
At a major transplant center in Indiana, despite similar levels of liver disease severity, Blacks had a lower transplant rate than whites.
GS-0976 lowered fibrosis biomarker levels but raised triglycerides in a Phase II study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.